- Site Map
Site Map
Pages
- About Us
- Biotech Showcase
- Contact Us
- Contract Manufacturing Facility
- CR845 Advances to Phase 2b in Chronic Pain
- Differentiate By Being Specific
- Download a Publication
- Download Corporate Overview Presentation
- Download Peptelligence® Brochure
- Enteris BioPharma and Cara Therapeutics’ CR845
- Enteris BioPharma and Tarsa Therapeutics’ TBRIA
- Enteris BioPharma Enhances Executive Leadership Team
- Enteris BioPharma Initiates Clinical Program for Tobrate™
- Enteris BioPharma Supports Endometriosis Awareness Month
- Enteris BioPharma to Present at BIO 2017
- Enteris BioPharma to Present at BioPharm America
- Enteris BioPharma to Present at Biotech Showcase 2019
- Enteris Doses First Woman in Phase 2a Clinical Trial for Endometriosis
- Enteris President & CFO to Present at Future Leaders
- Enteris to Present at BioCentury’s Future Leaders
- Enteris, KeyBioscience to Develop Solution for Metabolic Disorders
- Enteris, Sanofi to Develop Oral Therapeutic for Type 2 Diabetes
- Expanded Trial for Endometriosis Initiated
- Ferring Continues Peptide Development With Enteris
- Ferring, Enteris to Develop Oral Peptide Therapeutic
- First Patient Dosed in Phase 1 Trial of Oral (CR845) KORSUVA™
- First Patient Dosed in Trial of Oral KORSUVA™
- Formulation Technology
- Home
- News & Events
- Nordic BioScience
- Oral KORSUVA™ in Phase 2 Clinical Trial for Atopic Dermatitis
- Oral KORSUVA™ in Phase 2 Trial for Pruritus Treatment
- Oral Peptide Delivery Technology
- Ovarest®, Tobrate® at New Rhein Industry Day
- Partnering
- Peptelligence®-Tech and Cara’s CR845 Enters Phase 1 Trial
- Peptelligence®
- Pipeline
- Positive Results in Ovarest® Clinical Trial for Endometriosis Treatment
- Positive Results in Ovarest® Endometriosis Trial
- Scientific Advisory Board
- Site Map
- Terms of Use
- Thank You
- Timothy J. Saxon
Posts by category
- Category: Uncategorized
